The global BiosimilarsMarketwas valued at USD 3.23 billion in 2016 and is projected to reach USD 26.40 billion by 2025, growing at a CAGR of 26.29% from 2017 to 2025.
A biosimilar (also known as follow-on biologic or subsequent entry biologic) is a biologic medical product which is almost an identical copy of an original product.
Sample Infographics:
Market Dynamics:
1. Market Drivers
1.1 Rising Incidences of Diseases
1.2 Increasing Demand for Biosimilar Drugs Due to Their Cost-Effectiveness
1.3 Growing Pressure to Curtail Healthcare Expenditure
1.4 Growing Geriatric Population
1.5 Strategic Collaborations Resulting in Enhanced Productivity and Clinical Trial Activities for Biosimilars
1.6 Increasing Government Support
2. Market Restraints
2.1 Complexities in Manufacturing and High Costs
2.2 Innovative Strategies By Biologic Drug Manufacturers
Market Segmentation:
1. Global Biosimilars Market, by Application:
1.1 Oncology
1.2 Chronic and Autoimmune Diseases
1.3 Blood Disorders
1.4 Growth Hormone Deficiency
1.5 Infectious Diseases
1.6 Other Applications
2. Global Biosimilars Market, by Manufacturing:
2.1 In-House Manufacturing
2.2 Contract Manufacturing Organizations
3. Global Biosimilars Market, by Type Of Product:
3.1 Recombinant Non-Glycosylated Proteins
3.1.1 Insulin
3.1.2 Recombinant Human Growth Hormone (RHGH)
3.1.3 Granulocyte Colony-Stimulating Factor (Filgrastim)
3.1.4 Interferons
3.2 Recombinant Glycosylated Proteins
3.2.1 Erythropoietin (EPO)
3.2.2 Monoclonal Antibodies (MABS)
3.2.3 Follitropin
3.3 Recombinant Peptides
3.3.1 Glucagon
3.3.2 Calcitonin
4. Global Biosimilars Market, by Region:
4.1 North America (U.S., Canada, Mexico)
4.2 Europe (Germany, UK, France, Rest of Europe)
4.3 Asia Pacific (China, India, Japan, Rest of Asia Pacific)
4.4 Latin America (Brazil, Argentina, Rest of Latin America)
4.5 Middle East & Africa
Competitive Landscape:
The major players in the market are as follows:
1. Pfizer Inc.
2. Sandoz International GmbH (A Division of Novartis International AG)
3. Teva Pharmaceutical Industries Ltd.
4. F. Hoffmann-La Roche Ltd.
5. Amgen Inc.
6. Biocon Ltd.
7. Dr. Reddy's Laboratories
8. Celltrion Inc.
9. Mylan Inc.
10. Samsung Bioepis
These major players have adopted various organic as well as inorganic growth strategies such as mergers & acquisitions, new product launches, expansions, agreements, joint ventures, partnerships, and others to strengthen their position in this market.
RESEARCH METHODOLOGY OF VERIFIED MARKET INTELLIGENCE:
Research study on the BiosimilarsMarketwas performed in five phases which include Secondary research, Primary research, subject matter expert advice, quality check and final review.
The market data was analyzed and forecasted using market statistical and coherent models. Also market shares and key trends were taken into consideration while making the report. Apart from this, other data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Company Market Share Analysis, Standards of Measurement, Top to Bottom Analysis and Vendor Share Analysis.
To know more about the Research Methodology of Verified Market Intelligence and other aspects of the research study, kindly get in touch with our sales team.
1 INTRODUCTION OF GLOBAL BIOSIMILARS MARKET
1.1 Overview of the Market
1.2 Scope of Report
1.3 Assumptions
2 EXECUTIVE SUMMARY
3 RESEARCH METHODOLOGY OF VERIFIED MARKET INTELLIGENCE
3.1 Data Mining
3.2 Validation
3.3 Primary Interviews
3.4 List of Data Sources
4 GLOBAL BIOSIMILARSMARKETOUTLOOK
4.1 Overview
4.2 Market Dynamics
4.2.1 Drivers
4.2.2 Restraints
4.2.3 Opportunities
4.3 Porters Five Force Model
4.4 Value Chain Analysis
4.5 Regulatory Framework
5 GLOBAL BIOSIMILARS MARKET, BY APPLICATION
5.1 Oncology
5.2 Chronic and Autoimmune Diseases
5.3 Blood Disorders
5.4 Growth Hormone Deficiency
5.5 Infectious Diseases
5.6 Other Applications
6 GLOBAL BIOSIMILARS MARKET, BY MANUFACTURING
6.1 In-House Manufacturing
6.2 Contract Manufacturing Organizations
7 GLOBAL BIOSIMILARS MARKET, BY TYPE OF PRODUCT
7.1 Recombinant Non-Glycosylated Proteins
7.1.1 Insulin
7.1.2 Recombinant Human Growth Hormone (RHGH)
7.1.3 Granulocyte Colony-Stimulating Factor (Filgrastim)
7.1.4 Interferons
7.2 Recombinant Glycosylated Proteins
7.2.1 Erythropoietin (EPO)
7.2.2 Monoclonal Antibodies (MABS)
7.2.3 Follitropin
7.3 Recombinant Peptides
7.3.1 Glucagon
7.3.2 Calcitonin
8 GLOBAL BIOSIMILARSMARKET, BY GEOGRAPHY
8.1 Overview
8.2 North AmericaRegional Market Estimates and Forecasts, 2012 - 2025
8.2.1 U.S.
8.2.2 Canada
8.2.3 Mexico
8.3 EuropeRegional Market Estimates and Forecasts, 2012 - 2025
8.3.1 Germany
8.3.2 U.K.
8.3.3 France
8.3.4 Rest of Europe
8.4 Asia PacificRegional Market Estimates and Forecasts, 2012 - 2025
8.4.1 China
8.4.2 Japan
8.4.3 India
8.4.4 Rest of Asia Pacific
8.5 Latin AmericaRegional Market Estimates and Forecasts, 2012 - 2025
8.5.1 Brazil
8.5.2 Argentina
8.6 Rest of the WorldRegional Market Estimates and Forecasts, 2012 - 2025
9 GLOBAL BIOSIMILARSMARKETCOMPETITIVE LANDSCAPE
9.1 Overview
9.2 Company Market Share
9.3 Vendor Landscape
9.4 Key Development Strategies
10 COMPANY PROFILES
10.1 Pfizer Inc.
10.1.1 Overview
10.1.2 Financial Performance
10.1.3 Product Outlook
10.1.4 Key Developments
10.2 Sandoz International GmbH (A Division of Novartis International AG)
10.2.1 Overview
10.2.2 Financial Performance
10.2.3 Product Outlook
10.2.4 Key Developments
10.3 Teva Pharmaceutical Industries Ltd.
10.3.1 Overview
10.3.2 Financial Performance
10.3.3 Product Outlook
10.3.4 Key Developments
10.4 F. Hoffmann-La Roche Ltd.
10.4.1 Overview
10.4.2 Financial Performance
10.4.3 Product Outlook
10.4.4 Key Developments
10.5 Amgen Inc.
10.5.1 Overview
10.5.2 Financial Performance
10.5.3 Product Outlook
10.5.4 Key Developments
10.6 Biocon Ltd.
10.6.1 Overview
10.6.2 Financial Performance
10.6.3 Product Outlook
10.6.4 Key Developments
10.7 Dr. Reddy's Laboratories
10.7.1 Overview
10.7.2 Financial Performance
10.7.3 Product Outlook
10.7.4 Key Developments
10.8 Celltrion Inc.
10.8.1 Overview
10.8.2 Financial Performance
10.8.3 Product Outlook
10.8.4 Key Developments
10.9 Mylan Inc.
10.9.1 Overview
10.9.2 Financial Performance
10.9.3 Product Outlook
10.9.4 Key Developments
10.10 Samsung Bioepis
10.10.1 Overview
10.10.2 Financial Performance
10.10.3 Product Outlook
10.10.4 Key Developments
11 Appendix
11.1 Related Reports
The Biologics and Biosimilars CXO Services Market is set to witness immense growth during the forecast period 2024-2031. This intelligence report offers an in-depth analysis of the market size, share, growth, opportunity, competitive landsca...
Executive Summary
Azoth Analytics has released a research report titled Global Therapeutics Market (2024 Edition) which provides a complete analysis of the Global Therapeutics industry in terms of market segmentation By Molecule Type (Biologics and Biosimilars, Small Molecules), By Th...
Asia Pacific bioprocess technology market will grow by 15.0% annually with a total addressable market cap of $170.71 billion over 2024-2033. The growth is driven an increasing prevalence of chronic diseases, the widespread use of bioprocess technology, rising expenditures on R&D in the biotechnology...
Europe bioprocess technology market was valued at $6.56 billion in 2023 and will grow by 13.7% annually over 2023-2033. The growth is driven an increasing prevalence of chronic diseases, the widespread use of bioprocess technology, rising expenditures on R&D in the biotechnology sector, ongoing tech...
North America bioprocess technology market is projected to grow by 13.3% annually in the forecast period and reach $29.68 billion by 2033. The growth is driven an increasing prevalence of chronic diseases, the widespread use of bioprocess technology, rising expenditures on R&D in the biotechnology s...
Global bioprocess technology market will reach $88.39 billion by 2033, growing by 13.8% annually over 2023-2033. The growth is driven an increasing prevalence of chronic diseases, the widespread use of bioprocess technology, rising expenditures on R&D in the biotechnology sector, ongoing technologic...
Asia Pacific biopharmaceuticals market will grow by 10.3% annually with a total addressable market cap of $1,776.7 billion over 2024-2033, driven by the prevalence of chronic diseases along with aging population, rising investments in novel biopharma drugs, technological advancement for drug discove...
Europe biopharmaceuticals market was valued at $116.5 billion in 2023 and will grow by 8.6% annually over 2023-2033, driven by the prevalence of chronic diseases along with aging population, rising investments in novel biopharma drugs, technological advancement for drug discovery, growing clinical t...
North America biopharmaceuticals market is projected to grow by 8.4% annually in the forecast period and reach $407.2 billion by 2033, driven by the prevalence of chronic diseases along with aging population, rising investments in novel biopharma drugs, technological advancement for drug discovery, ...
Global biopharmaceuticals market will reach $1,001.1 billion by 2033, growing by 8.8% annually over 2023-2033. The growth is driven by the prevalence of chronic diseases along with aging population, rising investments in novel biopharma drugs, technological advancement for drug discovery, growing cl...